Worsening in ischemic stroke patients: is it time for a new strategy?
Caplan
L R
LR
D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects; D001929:Brain Edema / Q000150:complications; D020520:Brain Infarction / Q000150:complications; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D003428:Cross Infection / Q000150:complications; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D020244:Infarction, Middle Cerebral Artery / Q000150:complications; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010952:Plasma Substitutes / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D020521:Stroke / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D013997:Time Factors
D000925:Anticoagulants; D000959:Antihypertensive Agents; D018696:Neuroprotective Agents; D010952:Plasma Substitutes; D010975:Platelet Aggregation Inhibitors